Search | Clinical Trials Finder

Conditions: Short Stature, Growth Hormone Deficiency
Interventions: IGFBP-3 Stimulation Test; Procedure
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 4 Years to 12 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
Interventions: Testosterone Enanthate, Locomotor Training; Drug · Behavioral
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Polycystic Ovarian Syndrome in Adolescent Females, Vitamin D Deficiency
Interventions: Vitamin D 4000IU daily, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions: tesamorelin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • Boston, Massachusetts

Conditions: Growth Hormone Deficiency
Interventions: LUM-201, rhGH Norditropin® pen (34 µg/kg); Drug
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 27
States / cities: Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more

Conditions: Growth Hormone Deficiency
Interventions: Macimorelin, Arginine, Clonidine; Drug · Diagnostic Test
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Tucson, Arizona • Greenwood Village, Colorado • St. Petersburg, Florida + 9 more

Conditions: Primary Hyperparathyroidism, Hypercalcemia, Vitamin D Deficiency, Osteoporosis, Osteopenia
Interventions: Placebo, Vitamin D3; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 45 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Growth Hormone Deficiency
Interventions: Somatropin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1998
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions: TransCon hGH; Drug
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more

Conditions: Hurler Syndrome, Cerebral Palsy, Juvenile Rheumatoid Arthritis, Crohn Disease, HIV Infections
Interventions: Growth Hormone, Whole body Protein turnover, DEXA scan; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 3 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions: TransCon hGH; Drug
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more

Conditions: HIV Infection, Menopause
Interventions: Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Growth Hormone Deficiency (GHD)
Interventions: Saizen®; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: US Medical Information, Massachusetts

Conditions: Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
Interventions: Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin; Drug
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more

Conditions: Menopause
Interventions: No intervention; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pregnancy Related, Hormone Deficiency
Interventions: Proov Test; Diagnostic Test
Lead sponsor: MFB Fertility; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Brain Injuries, Growth Hormone Deficiency Dwarfism
Interventions: somatropin; Genetic
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 4
States / cities: Pittsburgh, Pennsylvania • El Paso, Texas • Salt Lake City, Utah + 1 more

Conditions: Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 3 Years to 14 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
Interventions: Determination of growth hormone status, Measurement of growth, thyroid and sex hormone levels, Behavior and neuropsychometric evaluations, Audiological and ear, nose and throat examination, Magnetic resonance imaging of the brain, Dysmorphology evaluation, Neurology examination, Dental evaluation, Speech pathology evaluation, Psychiatric evaluation, Orthopedic evaluation, Ophthalmologic evaluation, Gastrointestinal evaluation; Procedure
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1993 – 2040
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Growth Hormone Deficiency
Interventions: Not listed
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 18 Years to 25 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hormones
Interventions: NEA, DEA; Behavioral
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 28 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
Interventions: Increlex; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 20 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Growth Hormone Deficiency
Interventions: Somatropin; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 3 Years to 14 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 33
States / cities: Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more

Search by objective public record fields.

The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)

Prevention of Obesity in Women Via Estradiol Regulation

Tesamorelin Effects on Liver Fat and Histology in HIV

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D

Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

Effects of Growth Hormone in Chronically Ill Children

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Menopausal HT for Women Living With HIV (HoT)

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function

Relationship Between Fertility Hormone Patterns and Pregnancy Rates.

A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury

Constructing an Insulin-Like Growth Factor-based Prediction Model

Chromosome 18 Clinical Research Center

Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy

CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency